RLAY PEER ANALYSIS

Relay Therapeutics Inc — metric-by-metric comparison with peers and the industry median

RLAYRelay Therapeutics Inc

🇺🇸 USA · NASDAQ · Healthcare · Biotechnology

Value it Duel

Overall Profile & Returns

· Biotechnology

Position Within Industry

0 = weak quartile, 100 = strong quartile

RLAYIndustry median

Scores normalize each metric against industry quartiles (p25–p75); direction is inverted for lower-is-better metrics.

Return Comparison

1-Year

Split-adjusted

Year-to-Date (YTD)

Key Metric Comparison

P/E

Lower is better

ROE

Higher is better

Net Margin

Higher is better

Revenue Growth

Higher is better

All Metrics

Valuation
Metric	RLAY	TLX	MSB	CSL	Ind. Median
P/E	—	—	—	29.96	18.06
P/B	5.53	6.38	—	2.24●	3.62
EV/EBITDA	—	120.20	—	10.35●	15.13
P/S	332.51	3.24	31.30	2.66●	10.65

Financial Health
Metric	RLAY	TLX	MSB	CSL	Ind. Median
Current Ratio	22.13●	1.43	—	2.57	5.90
Debt/Equity	4.9%●	112.3%	—	67.4%	10.9%
NetDebt/EBITDA	2.23	13.13	—	2.22●	1.15

Profitability
Metric	RLAY	TLX	MSB	CSL	Ind. Median
Net Margin	-2,554.1%	-0.9%	-115.3%	9.2%●	-125.7%
ROE	-40.0%	-1.8%	-11.3%	7.7%●	-47.5%
ROA	-36.4%	-0.7%	-8.6%	3.8%●	-35.8%
EBITDA Margin	-2,560.7%	3.0%	-76.6%	32.8%●	-105.8%

Growth + Dividend
Metric	RLAY	TLX	MSB	CSL	Ind. Median
Rev. Growth	39.0%	56.3%	410.4%●	4.8%	5.1%
NI Growth	—	—	—	-39.4%	12.1%
Div. Yield	—	—	0.0%	2.5%●	0.2%
Payout	—	—	0.0%	103.1%	0.0%

Valuation
Metric	RLAY	RARE	IDYA	ARQT	BEAM	ELVN	Ind. Median
P/E	—	—	—	—	—	—	18.06
P/B	5.53	-15.29●	3.83	18.87	3.36	7.05	3.62
EV/EBITDA	—	—	—	224.16	—	—	15.13
P/S	332.51	5.39●	15.95	8.61	23.87	—	10.65

Financial Health
Metric	RLAY	RARE	IDYA	ARQT	BEAM	ELVN	Ind. Median
Current Ratio	22.13	2.02	10.74	2.68	16.99	40.32●	5.90
Debt/Equity	4.9%	-508.5%●	3.1%	7.0%	21.5%	0.1%	10.9%
NetDebt/EBITDA	2.23	-1.56	4.74	-14.03●	30.00	4.59	1.15

Profitability
Metric	RLAY	RARE	IDYA	ARQT	BEAM	ELVN	Ind. Median
Net Margin	-2,554.1%	-91.0%	-62.2%	-0.6%●	-39.7%	—	-125.7%
ROE	-40.0%	—	-14.3%	-1.4%●	-5.7%	-26.6%	-47.5%
ROA	-36.4%	-46.7%	-13.1%	-0.6%●	-4.4%	-25.7%	-35.8%
EBITDA Margin	-2,560.7%	-75.2%	-60.1%	3.6%●	-19.5%	—	-105.8%

Growth + Dividend
Metric	RLAY	RARE	IDYA	ARQT	BEAM	ELVN	Ind. Median
Rev. Growth	39.0%	13.3%	3,118.1%●	95.3%	158.0%	-100.0%	5.1%
NI Growth	—	—	—	—	—	—	12.1%
Div. Yield	—	—	—	—	—	—	0.2%
Payout	—	—	—	—	—	—	0.0%

The green dot marks the best value in the group given the metric direction (higher/lower is better). All metrics use trailing-twelve-month (TTM) data.

Go deeper on RLAY

Run a DCF valuation

Full DCF model with editable assumptions

Start a head-to-head duel

Compare two stocks metric by metric

Filter in the stock screener

Build your own universe with 400+ metrics

Data on this page refreshes once per day. Price data as of Jul 7, 26. This content is for informational purposes only and is not investment advice.